Evidence map›Paper›PMID 38455906›Full record

ArticleFrontiers in epidemiology2023

Tracking SARS-CoV-2 seropositivity in rural communities using blood-fed mosquitoes: a proof-of-concept study.

Benjamin J Krajacich, Djibril Samaké, Adama Dao, Moussa Diallo, Zana Lamissa Sanogo, Alpha Seydou Yaro, Amatigue Zeguime, Josué Poudiougo, Kadiatou Cissé, Mamadou Traoré and 6 more

Open access · diamondAbstract read
In one paragraph

Article in Frontiers in epidemiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 69% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Benjamin J Krajacich *Laboratory of Malaria and Vector Research, NIAID, NIH, Rockville, MD, United States.
Djibril SamakéMalaria Research and Training Center (MRTC)/Faculty of Medicine, Pharmacy and Odonto-Stomatology, University of Sciences, Techniques and Technologies, Bamako, Mali.
Adama Dao *Malaria Research and Training Center (MRTC)/Faculty of Medicine, Pharmacy and Odonto-Stomatology, University of Sciences, Techniques and Technologies, Bamako, Mali.
Moussa DialloMalaria Research and Training Center (MRTC)/Faculty of Medicine, Pharmacy and Odonto-Stomatology, University of Sciences, Techniques and Technologies, Bamako, Mali.
Zana Lamissa SanogoMalaria Research and Training Center (MRTC)/Faculty of Medicine, Pharmacy and Odonto-Stomatology, University of Sciences, Techniques and Technologies, Bamako, Mali.
Alpha Seydou YaroMalaria Research and Training Center (MRTC)/Faculty of Medicine, Pharmacy and Odonto-Stomatology, University of Sciences, Techniques and Technologies, Bamako, Mali.
Amatigue ZeguimeMalaria Research and Training Center (MRTC)/Faculty of Medicine, Pharmacy and Odonto-Stomatology, University of Sciences, Techniques and Technologies, Bamako, Mali.
Josué PoudiougoMalaria Research and Training Center (MRTC)/Faculty of Medicine, Pharmacy and Odonto-Stomatology, University of Sciences, Techniques and Technologies, Bamako, Mali.
Kadiatou CisséMalaria Research and Training Center (MRTC)/Faculty of Medicine, Pharmacy and Odonto-Stomatology, University of Sciences, Techniques and Technologies, Bamako, Mali.
Mamadou TraoréMalaria Research and Training Center (MRTC)/Faculty of Medicine, Pharmacy and Odonto-Stomatology, University of Sciences, Techniques and Technologies, Bamako, Mali.
Alassane Dit AssitounMalaria Research and Training Center (MRTC)/Faculty of Medicine, Pharmacy and Odonto-Stomatology, University of Sciences, Techniques and Technologies, Bamako, Mali.
Roy FaimanLaboratory of Malaria and Vector Research, NIAID, NIH, Rockville, MD, United States.
Irfan ZaidiLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
John WoodfordLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Patrick E DuffyLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Tovi LehmannLaboratory of Malaria and Vector Research, NIAID, NIH, Rockville, MD, United States.
Vector Oncology (United States) · USNational Institutes of Health · USNational Institute of Allergy and Infectious Diseases · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The spread of SARS-CoV-2 cannot be well monitored and understood in areas without capacity for effective disease surveillance. Countries with a young population will have disproportionately large numbers of asymptomatic or pauci-symptomatic infections, further hindering detection of infection. Sero-surveillance on a country-wide scale by trained medical professionals may be limited in a resource-limited setting such as Mali. Novel ways of broadly sampling the human population in a non-invasive method would allow for large-scale surveillance at a reduced cost. Approach: Here we evaluate the collection of naturally blood-fed mosquitoes to test for human anti-SARS-CoV-2 antibodies in the laboratory and at five field locations in Mali. Results: Immunoglobulin-G antibodies to multiple SARS-CoV-2 antigens were readily detected in mosquito bloodmeals by bead-based immunoassay through at least 10 h after feeding [mean sensitivity of 0.92 (95% CI 0.78-1) and mean specificity of 0.98 (95% CI 0.88-1)], indicating that most blood-fed mosquitoes collected indoors during early morning hours (and likely to have fed the previous night) are viable samples for analysis. We found that reactivity to four SARS-CoV-2 antigens rose during the pandemic from pre-pandemic levels. The crude seropositivity of blood sampled via mosquitoes was 6.3% in October and November 2020 across all sites, and increased to 25.1% overall by February 2021, with the most urban site reaching 46.7%, consistent with independent venous blood-based sero-surveillance estimates. Conclusions: We have demonstrated that using mosquito bloodmeals, country-wide sero-surveillance of human diseases (both vector-borne and non-vector-borne) is possible in areas where human-biting mosquitoes are common, offering an informative, cost-effective, and non-invasive sampling option.

Indexed as

AfricaCOVID-19mosquito bloodmealpopulation-based epidemiologysero-surveillance

Identifiers

PMID38455906
PMCPMC10911011
OpenAlexW4389686820

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.